PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
iNtRON Biotechnology maintains cash-generating molecular diagnostics and animal antibiotic-alternative businesses while pursuing re-licensing of its bacteriophage endolysin drug candidate SAL200, even as annual operating losses widen and shareholder equity erodes.
2025 revenue fell to KRW 5.74 billion, the fourth straight annual decline, while operating loss widened to KRW 7.90 billion
Quarterly revenue over the trailing four quarters (2025Q3-2026Q2) showed a recovering trend, rising to KRW 2.03 billion in 2026Q2
Core pipeline candidate SAL200 remains under a conditional evaluation-and-option agreement with Switzerland's Basilea, with conversion to a definitive license still pending
The company will present its first oncology-related findings, IMPA phage engineering data on colorectal cancer, at ESMO 2026 in October
Shareholder equity shrank from KRW 106.18 billion in 2022 to KRW 69.87 billion in 2025, and operating cash flow turned negative in 2025
iNtRON Biotechnology is a biotech venture built on bacteriophage (viruses that infect bacteria) and endolysin protein platform technology.
To offset the long investment horizon typical of drug development, the company operates cash-generating businesses alongside its new drug pipeline, with molecular diagnostics (the DR unit) and bacteriophage-based animal antibiotic alternatives serving as the two revenue-producing pillars.
The DR unit develops and sells molecular diagnostic and rapid antigen test kits using PCR and chromatography platform technology.
The business is composed of a new drug unit based on bacteriophage platform technology and a DR unit that develops diagnostic kits, including molecular diagnostics and rapid antigen tests, using PCR and chromatography platform technology.
The animal antibiotic-alternative segment commercializes products derived from natural bacteriophages; the company has commercialized bacteriophage-based animal antibiotic alternatives to address the serious problems of conventional synthetic antibiotics, and has also generated baseline revenue through molecular diagnostic technologies such as COVID-19 test kits.
The new drug segment's revenue consists of technology out-licensing, research service, and royalty income, with its flagship pipeline being SAL200, an endolysin candidate targeting multidrug-resistant Staphylococcus aureus (MRSA/VRSA).
The drug platform is split into two arms: itLysin, an endolysin engineering platform for antimicrobial-resistance drugs, and IMPA, a bacteriophage engineering platform being extended into immuno-oncology, and pipelines are being developed based on the itLysin platform technology, while various pipelines including colorectal cancer treatments are being developed based on the IMPA platform technology.
The company recently disclosed its first oncology-related research using the IMPA platform at an academic conference, broadening its drug pipeline into the oncology space, and it will present two posters on IMPA phage engineering research targeting colorectal cancer at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain in October 2026.
On the competitive front, a growing number of domestic biotechs are eyeing the animal health market as a new business development frontier, which could intensify competition in iNtRON's existing animal antibiotic-alternative business.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩1.2B | -₩2B | −159.5% |
| 2025Q3 | ₩1.6B | -₩2.1B | −127.3% |
| 2025Q4 | ₩1.7B | -₩2B | −119.8% |
| 2026Q1 | ₩1.9B | -₩2.2B | −115.0% |
| 2026Q2 | ₩2B | -₩1.6B | −80.4% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩14B | -₩1.5B | ₩5.7B | −10.6% | 5.4% | 32.8% |
| 2023 | ₩9.6B | -₩3.3B | -₩9.7B | −34.3% | −10.0% | 1.9% |
| 2024 | ₩6.4B | -₩5.2B | -₩2.6B | −81.6% | −3.1% | 3.1% |
| 2025 | ₩5.7B | -₩7.9B | -₩9B | −137.7% | −12.8% | 6.4% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-24
Annual revenue at iNtRON Biotechnology declined for four consecutive years, falling from KRW 14.01 billion in 2022 to KRW 9.59 billion in 2023, KRW 6.42 billion in 2024, and KRW 5.74 billion in 2025.
Operating losses widened every year over the same period, from KRW 1.48 billion in 2022 to KRW 3.28 billion in 2023, KRW 5.24 billion in 2024, and KRW 7.90 billion in 2025, as declining revenue combined with fixed-cost burden to erode profitability.
The 2025 operating margin stood at -137.7%, a sharp deterioration from -10.6% four years earlier.
Net income was positive at KRW 5.71 billion in 2022, likely reflecting a one-off item, but the company remained in the red thereafter, posting net losses of KRW 9.70 billion in 2023, KRW 2.59 billion in 2024, and KRW 8.96 billion in 2025.
On a quarterly basis, revenue rose for five straight quarters, from KRW 1.23 billion in 2025Q2 to KRW 1.62 billion in 2025Q3, KRW 1.70 billion in 2025Q4, KRW 1.88 billion in 2026Q1, and KRW 2.03 billion in 2026Q2, showing a recovery from the trough.
Over the same window, the quarterly operating loss widened from KRW 1.96 billion in 2025Q2 to KRW 2.17 billion in 2026Q1 before narrowing to KRW 1.64 billion in 2026Q2, the smallest loss of the trailing four quarters.
The 2025Q4 net loss of KRW 4.15 billion, however, stands out as notably larger than other quarters and appears to reflect a one-off item, while 2026Q1 and 2026Q2 net losses were similar at roughly KRW 2.26 billion each.
The trailing-four-quarter (2025Q3-2026Q2) net loss totaled KRW 10.34 billion, indicating the company remains in a substantial loss-making phase even on an annualized basis.
On the balance sheet, shareholder equity continued to shrink from KRW 106.18 billion in 2022 to KRW 69.87 billion in 2025, while operating cash flow, positive in 2022-2023, was roughly breakeven in 2024 (-KRW 0.14 billion) before deteriorating sharply to -KRW 5.21 billion in 2025.
The global antimicrobial resistance (AMR) crisis, driven by the spread of multidrug-resistant bacterial infections, continues to stimulate demand for new antibacterial mechanisms, and endolysin- and bacteriophage-based drugs are gaining attention as alternatives to conventional chemical antibiotics. iNtRON's SAL200 is a candidate in this field that has completed Phase 1a/1b and Phase 2a trials in Korea, accumulating safety and antibacterial efficacy data.
The company stated that SAL200 demonstrated strong antibacterial efficacy against coagulase-negative Staphylococci (CoNS), which it said carries important implications for treating infective endocarditis.
However, commercialization in the new drug segment is heavily dependent on successfully concluding licensing agreements, and there is a history of partnering risk: SAL200 was out-licensed to a Roivant affiliate in Switzerland in 2018 but had its rights returned in 2022.
The cash-cow segments of animal antibiotic alternatives and molecular diagnostics are relatively stable, but the domestic animal medicine market's growth rate reportedly trails the global average.
According to Korea's Ministry of Agriculture, Food and Rural Affairs, the domestic animal medicine market is expected to grow at a compound annual rate of 5% between 2022 and 2027, lower than the global average of 7.7% and lower than major Asian countries excluding Japan.
Against this backdrop, a growing number of domestic biotechs are exploring animal health as a new business development frontier, and the animal medicine market has already been identified as a future growth driver by domestic pharmaceutical companies including Daewoong Pharmaceutical, Yuhan Corporation, and HK inno.N.
This could intensify competitive pressure on iNtRON's existing cash-cow businesses.
Taken together, the new drug segment targets a market with significant unmet medical need in antibiotic-resistant infections but hinges on successful licensing, while the cash-cow segment offers stability with more limited growth potential.
The company has identified re-licensing of SAL200 as its top priority. CEO Yun Kyung-won stated at a press briefing that out-licensing is an absolute goal, adding that the main target for the year is an additional out-license for SAL200, though it could slip to the following year.
A conditional evaluation-and-option agreement with Switzerland's Basilea has been in place since October 2023, under which Basilea decided to pursue an internal evaluation study to review possible dose adjustments for the upcoming FDA Phase 2 trial, and entered into the option agreement to secure usage rights for SAL200 during that period.
Whether this evaluation converts into a definitive licensing agreement is the key point to watch.
On indication expansion, beyond the endocarditis treatment focus, the company is also pursuing development for surgical site infection (SSI) prevention, and it announced plans to conduct trials this year to expand SAL200's indication to an SSI formulation, aiming for a trial design that leverages the previously demonstrated safety profile rather than a fresh Phase 2 entry.
On the manufacturing front, the company has continued technical upgrades; according to its corporate site, it secured enhanced production technology for a foam formulation of bacteriophages in August 2026 that increased single-batch output, alongside earlier announcements in July 2026 of localizing key molecular diagnostic biomaterials and filing a patent for a subcutaneous formulation change.
In terms of pipeline expansion, the company is set to present its first oncology data, based on the IMPA platform targeting colorectal cancer, at the ESMO Congress in October 2026, which will serve as a test of the platform's extension into oncology.
iNtRON Biotechnology has remained in a net loss position for multiple years, a period in which earnings-based valuation comparisons carry limited meaning. The stock trades at a certain premium to net asset value, which may partly reflect market expectations around pipeline licensing prospects.
The company currently pays no dividend, making dividend-based metrics difficult to apply.
Profitability over recent years has moved from a positive result in 2022 to consecutive net losses thereafter, and while quarterly revenue has shown a recovering trend, a clear improvement in operating profitability has yet to materialize—suggesting the valuation the market assigns may be more sensitive to pipeline events such as licensing deals or clinical readouts than to reported earnings.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-24
Revenue over the trailing four quarters rose for five consecutive quarters, from KRW 1.23 billion in 2025Q2 to KRW 2.03 billion in 2026Q2. Over the same period, the operating loss also narrowed from KRW 2.17 billion in 2026Q1 to KRW 1.64 billion in 2026Q2. Continued revenue recovery could indicate an expanding contribution from the cash-cow businesses.
The company has set out-licensing of SAL200 as its top priority and continues partnership discussions through a conditional option agreement with Basilea in Switzerland. It recently disclosed additional antibacterial efficacy data against CoNS, reinforcing its clinical evidence base. It should be noted, however, that this remains an ongoing negotiation rather than a confirmed contract.
Colorectal cancer research results using the IMPA phage engineering platform are set to be presented for the first time at ESMO in October 2026. This represents a test of whether the pipeline, historically centered on antimicrobial resistance, can extend into oncology.
A successful demonstration of the technology could broaden the basis for discussions with global pharmaceutical partners.
Annual operating losses widened for four straight years, from KRW 1.48 billion in 2022 to KRW 7.90 billion in 2025, while shareholder equity fell from KRW 106.18 billion to KRW 69.87 billion over the same period.
The simultaneous decline in revenue and widening of losses points to a continued weakening of financial strength.
Operating cash flow remained positive in 2022-2023 but was roughly breakeven in 2024 (-KRW 0.14 billion) before deteriorating sharply to -KRW 5.21 billion in 2025. If this trend persists, the need for external financing could increase.
SAL200 was out-licensed to a Roivant affiliate in 2018, but the rights were returned in 2022.
The current relationship with Basilea also remains at a conditional evaluation-and-option stage rather than a definitive agreement, and the possibility that conversion to a binding license could take longer or fail to materialize cannot be ruled out.
SAL200 has completed Phase 1a/1b and Phase 2a trials in Korea and received FDA approval for a Phase 2 trial, but large-scale registration trial results have not yet been confirmed. Trial failure or delays could affect the overall commercialization timeline.
The relationship with Basilea remains at the conditional evaluation-and-option stage, with the timing and likelihood of conversion to a definitive agreement uncertain. Given the prior termination of the Roivant affiliate agreement via rights reversion, a similar outcome cannot be ruled out.
With operating cash flow deteriorating to -KRW 5.21 billion in 2025 amid persistent net losses, additional financing may be required to fund future drug development costs, which could raise the possibility of shareholder dilution through means such as rights offerings.
Two posters on IMPA phage engineering research targeting colorectal cancer are scheduled to be presented at the ESMO Congress 2026, offering an early read on the reception of the company's oncology pipeline expansion.
2026Q3 earnings are expected to be disclosed under the standard 45-day reporting rule, and it will be worth checking whether the recent trend of quarterly revenue recovery and narrowing operating losses continues.
It will be important to monitor for disclosures on the initiation of SAL200's surgical site infection (SSI) indication expansion trial and on any conversion of the Basilea agreement into a definitive license.
iNtRON Biotechnology maintains its revenue base through cash-generating molecular diagnostics and animal antibiotic-alternative businesses, while pursuing re-licensing of its bacteriophage endolysin drug candidate SAL200 as a core growth driver.
Financially, the company has shown a clear pattern of four consecutive years of declining revenue, widening operating losses, and shrinking equity, though the trailing four quarters showed a recovering trend with revenue rising for five straight quarters.
SAL200 remains at the conditional evaluation-and-option stage with Switzerland's Basilea, and whether this converts into a definitive license is the key variable shaping the future direction of the new drug segment.
The move into colorectal cancer research via the IMPA platform represents an attempt at pipeline diversification, with initial results due to be unveiled at ESMO in October 2026. However, the shift of operating cash flow into negative territory in 2025 is a factor that could translate into future financing pressure.
Investors should continue to monitor events such as quarterly earnings releases, progress on the Basilea agreement, and the initiation of the SSI indication expansion trial.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.